Advertisement

Interferon as a Mucosal Adjuvant for an Influenza Vaccine in Pigs

  • Lirong Liu
  • Wenhui Fan
  • He Zhang
  • Shuang Zhang
  • Liang Cui
  • Meng Wang
  • Xiaoyuan Bai
  • Wenxian Yang
  • Lei Sun
  • Limin Yang
  • Wenjun LiuEmail author
  • Jing LiEmail author
RESEARCH ARTICLE
  • 102 Downloads

Abstract

Interferon, a natural protein that is produced by a variety of cells during viral infection, activates the transcription of multiple functional genes in cells, regulates synergy among various signaling pathways, and mediates many biological functions such as antiviral activity, immune regulation, and cell growth. However, clinical research on interferon in livestock is lacking. In this study, recombinant porcine interferon (PoIFNα) was used as an adjuvant, in combination with inactivated influenza virus, to vaccinate 6-week-old pigs via nasal infusion. The transcription of target genes was then monitored and the functions of PoIFNα were determined with respect to the activation of mucosal immunity. We found that a combination of low-dose PoIFNα and inactivated influenza virus could significantly up-regulate the expression of immunoregulatory cytokines such as IL-2, IL-18, IFN-γ, IL-6, and IL-10 by real-time PCR, suggesting the induction of a strong mucosal innate immune response after administration. In addition, low-dose PoIFNα can significant enhancing the transcription of genes encoding homing factors including CCR9 and CCR10 (P < 0.001), thereby resulting in the induction of higher levels of HA-specific antibodies (P < 0.05), which can be determined by ELISA and IFA. Post-immunization challenges with H1N1 virus demonstrated that PoIFNα, combined with inactivated influenza virus, could alleviate clinical signs in pigs during the early stages of viral infection. These studies reveal low-dose PoIFNα as a potential mucosal adjuvant for influenza virus in pigs.

Keywords

Porcine interferon α (PoIFNα) H1N1 influenza virus Intranasal administration Cytokines 

Notes

Acknowledgements

We gratefully acknowledge the workers of Beijing Sinder Technology Co., Ltd. for their help with pig immunization and sample collection. This work was supported by Grants from the National Key R&D Programme of China (2017YFD051105), the National Natural Science Foundation of China (31630079), the National Science and Technology Major Project (2018ZX10101004), and the Strategic Priority Research Program of the Chinese Academy of Sciences (XDB29010000). W.J.L. is the principal investigator of the Innovative Research Group of the National Natural Science Foundation of China (Grant No. 81621091). J.L. is supported by Youth Innovation Promotion Association of CAS (2019).

Author Contributions

JL and WL supervised the Project and designed the study; JL and LL planned and conducted the experimental work, analyzed the data, and wrote the manuscript; WF, HZ, SZ, LC, MW, XB, WY, LY, and LS provided technical support. All authors read and approved the final manuscript.

Compliance with Ethical Standards

Conflicts of interest

All authors declare that they have no conflict of interest.

Animal and Human Rights Statement

The pig experimental design and protocols used in this study were approved by the Institute of Microbiology, Chinese Academy of Sciences of Research Ethics Committee (Permit Number: PZIMCAS2017001). All pig experimental procedures were performed in accordance with the Regulations for the Administration of Affairs Concerning Experimental Animals approved by the State Council of People’s Republic of China.

Supplementary material

12250_2019_102_MOESM1_ESM.pdf (427 kb)
Supplementary material 1 (PDF 427 kb)

References

  1. Arend WP, Palmer G, Gabay C (2008) IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev 223:20–38CrossRefGoogle Scholar
  2. Beilharz MW, McDonald W, Watson MW, Heng J, McGeachie J, Lawson CM (1997) Low-dose oral type I interferons reduce early virus replication of murine cytomegalovirus in vivo. J Interferon Cytokine Res 17:625–630CrossRefGoogle Scholar
  3. Biron CA (2001) Interferons alpha and beta as immune regulators–a new look. Immunity 14:661–664CrossRefGoogle Scholar
  4. Bracci L, Canini I, Puzelli S, Sestili P, Venditti M, Spada M, Donatelli I, Belardelli F, Proietti E (2005) Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level. Vaccine 23:2994–3004CrossRefGoogle Scholar
  5. Braun D, Caramalho I, Demengeot J (2002) IFN-alpha/beta enhances BCR-dependent B cell responses. Int Immunol 14:411–419CrossRefGoogle Scholar
  6. Brod SA, Nelson L, Jin R, Wolinsky JS (1999) Ingested interferon alpha induces Mx mRNA. Cytokine 11:492–499CrossRefGoogle Scholar
  7. Brown IH (2000) The epidemiology and evolution of influenza viruses in pigs. Vet Microbiol 74:29–46CrossRefGoogle Scholar
  8. Chen C, Li J, Bi Y, Yang L, Meng S, Zhou Y, Jia X, Meng S, Sun L, Liu W (2013) Synthetic B- and T-cell epitope peptides of porcine reproductive and respiratory syndrome virus with Gp96 as adjuvant induced humoral and cell-mediated immunity. Vaccine 31:1838–1847CrossRefGoogle Scholar
  9. Cheng G, Zhao X, Yan W, Wang W, Zuo X, Huang K, Liu Y, Chen J, Wang J, Cong W, Liu M, Gao H, Chen J, Lu Y, Zheng Z (2007) Alpha interferon is a powerful adjuvant for a recombinant protein vaccine against foot-and-mouth disease virus in swine, and an effective stimulus of in vivo immune response. Vaccine 25:5199–5208CrossRefGoogle Scholar
  10. Chiou CJ, Tseng LP, Deng MC, Jiang PR, Tasi SL, Chung TW, Huang YY, Liu DZ (2009) Mucoadhesive liposomes for intranasal immunization with an avian influenza virus vaccine in chickens. Biomaterials 30:5862–5868CrossRefGoogle Scholar
  11. da Cunha IA, Zulpo DL, Bogado AL, de Barros LD, Taroda A, Igarashi M, Navarro IT, Garcia JL (2012) Humoral and cellular immune responses in pigs immunized intranasally with crude rhoptry proteins of Toxoplasma gondii plus Quil-A. Vet Parasitol 186:216–221CrossRefGoogle Scholar
  12. Dawson HD, Beshah E, Nishi S, Solano-Aguilar G, Morimoto M, Zhao A, Madden KB, Ledbetter TK, Dubey JP, Shea-Donohue T, Lunney JK, Urban JF Jr (2005) Localized multigene expression patterns support an evolving Th1/Th2-like paradigm in response to infections with Toxoplasma gondii and Ascaris suum. Infect Immun 73:1116–1128CrossRefGoogle Scholar
  13. Diaz-San Segundo F, Moraes MP, de Los Santos T, Dias CC, Grubman MJ (2010) Interferon-induced protection against foot-and-mouth disease virus infection correlates with enhanced tissue-specific innate immune cell infiltration and interferon-stimulated gene expression. J Virol 84:2063–2077CrossRefGoogle Scholar
  14. Duvigneau JC, Hartl RT, Groiss S, Gemeiner M (2005) Quantitative simultaneous multiplex real-time PCR for the detection of porcine cytokines. J Immunol Methods 306:16–27CrossRefGoogle Scholar
  15. Eisfeld AJ, Neumann G, Kawaoka Y (2015) At the centre: influenza A virus ribonucleoproteins. Nat Rev Microbiol 13:28–41CrossRefGoogle Scholar
  16. Feng N, Jaimes MC, Lazarus NH, Monak D, Zhang C, Butcher EC, Greenberg HB (2006) Redundant role of chemokines CCL25/TECK and CCL28/MEC in IgA + plasmablast recruitment to the intestinal lamina propria after rotavirus infection. J Immunol 176:5749–5759CrossRefGoogle Scholar
  17. Foster N, Hulme SD, Barrow PA (2003) Induction of antimicrobial pathways during early-phase immune response to Salmonella spp. in murine macrophages: gamma interferon (IFN-gamma) and upregulation of IFN-gamma receptor alpha expression are required for NADPH phagocytic oxidase gp91-stimulated oxidative burst and control of virulent Salmonella spp. Infect Immun 71:4733–4741CrossRefGoogle Scholar
  18. Giacomini P, Tecce R, Gambari R, Sacchi A, Fisher PB, Natali PG (1988) Recombinant human IFN-gamma, but not IFN-alpha or IFN-beta, enhances MHC- and non-MHC-encoded glycoproteins by a protein synthesis-dependent mechanism. J Immunol 140:3073–3081Google Scholar
  19. Goodbourn S, Didcock L, Randall RE (2000) Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J Gen Virol 81:2341–2364CrossRefGoogle Scholar
  20. Gosling J, Dairaghi DJ, Wang Y, Hanley M, Talbot D, Miao Z, Schall TJ (2000) Cutting edge: identification of a novel chemokine receptor that binds dendritic cell- and T cell-active chemokines including ELC, SLC, and TECK. J Immunol 164:2851–2856CrossRefGoogle Scholar
  21. Hilbert DM, Cancro MP, Scherle PA, Nordan RP, Van Snick J, Gerhard W, Rudikoff S (1989) T cell derived IL-6 is differentially required for antigen-specific antibody secretion by primary and secondary B cells. J Immunol 143:4019–4024Google Scholar
  22. Hromadnikova I, Li S, Kotlabova K, Dickinson AM (2016) Influence of in vitro IL-2 or IL-15 alone or in combination with Hsp 70 derived 14-mer peptide (TKD) on the expression of NK cell activatory and inhibitory receptors on peripheral blood T Cells, B Cells and NKT cells. PLoS ONE 11:e0151535CrossRefGoogle Scholar
  23. Hu L, Lin XY, Yang ZX, Yao XP, Li GL, Peng SZ, Wang Y (2015) A multiplex PCR for simultaneous detection of classical swine fever virus, African swine fever virus, highly pathogenic porcine reproductive and respiratory syndrome virus, porcine reproductive and respiratory syndrome virus and pseudorabies in swines. Pol J Vet Sci 18:715–723CrossRefGoogle Scholar
  24. Hyland K, Foss DL, Johnson CR, Murtaugh MP (2004) Oral immunization induces local and distant mucosal immunity in swine. Vet Immunol Immunopathol 102:329–338CrossRefGoogle Scholar
  25. Itoh K, Hirohata S (1995) The role of IL-10 in human B cell activation, proliferation, and differentiation. J Immunol 154:4341–4350Google Scholar
  26. Lazarus NH, Kunkel EJ, Johnston B, Wilson E, Youngman KR, Butcher EC (2003) A common mucosal chemokine (mucosae-associated epithelial chemokine/CCL28) selectively attracts IgA plasmablasts. J Immunol 170:3799–3805CrossRefGoogle Scholar
  27. Le Bon A, Schiavoni G, D’Agostino G, Gresser I, Belardelli F, Tough DF (2001) Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14:461–470CrossRefGoogle Scholar
  28. Lee YJ, Lee C (2012) Cytokine production in immortalized porcine alveolar macrophages infected with porcine reproductive and respiratory syndrome virus. Vet Immunol Immunopathol 150:213–220CrossRefGoogle Scholar
  29. Lung O, Beeston A, Ohene-Adjei S, Pasick J, Hodko D, Hughes KB, Furukawa-Stoffer T, Fisher M, Deregt D (2012) Electronic microarray assays for avian influenza and Newcastle disease virus. J Virol Methods 185:244–253CrossRefGoogle Scholar
  30. Mamber SW, Lins J, Gurel V, Hutcheson DP, Pinedo P, Bechtol D, Krakowka S, Fields-Henderson R, Cummins JM (2016) Low-dose oral interferon modulates expression of inflammatory and autoimmune genes in cattle. Vet Immunol Immunopathol 172:64–71CrossRefGoogle Scholar
  31. McBride S, Hoebe K, Georgel P, Janssen E (2006) Cell-associated double-stranded RNA enhances antitumor activity through the production of type I IFN. J Immunol 177:6122–6128CrossRefGoogle Scholar
  32. Meng S, Yang L, Xu C, Qin Z, Xu H, Wang Y, Sun L, Liu W (2011) Recombinant chicken interferon-alpha inhibits H9N2 avian influenza virus replication in vivo by oral administration. J Interferon Cytokine Res 31:533–538CrossRefGoogle Scholar
  33. Meurens F, Berri M, Whale J, Dybvig T, Strom S, Thompson D, Brownlie R, Townsend HG, Salmon H, Gerdts V (2006) Expression of TECK/CCL25 and MEC/CCL28 chemokines and their respective receptors CCR9 and CCR10 in porcine mucosal tissues. Vet Immunol Immunopathol 113:313–327CrossRefGoogle Scholar
  34. Myers KP, Olsen CW, Gray GC (2007) Cases of swine influenza in humans: a review of the literature. Clin Infect Dis 44:1084–1088CrossRefGoogle Scholar
  35. Namangala B, Inoue N, Kohara J, Kuboki N, Sakurai T, Hayashida K, Sugimoto C (2006) Evidence for the immunostimulatory effects of low-dose orally delivered human IFN-alpha in cattle. J Interferon Cytokine Res 26:675–681CrossRefGoogle Scholar
  36. Ogawa H, Taira O, Hirai T, Takeuchi H, Nagao A, Ishikawa Y, Tuchiya K, Nunoya T, Ueda S (2009) Multiplex PCR and multiplex RT-PCR for inclusive detection of major swine DNA and RNA viruses in pigs with multiple infections. J Virol Methods 160:210–214CrossRefGoogle Scholar
  37. O’Keefe GM, Nguyen VT, Benveniste EN (1999) Class II transactivator and class II MHC gene expression in microglia: modulation by the cytokines TGF-beta, IL-4, IL-13 and IL-10. Eur J Immunol 29:1275–1285CrossRefGoogle Scholar
  38. Proietti E, Bracci L, Puzelli S, Di Pucchio T, Sestili P, De Vincenzi E, Venditti M, Capone I, Seif I, De Maeyer E, Tough D, Donatelli I, Belardelli F (2002) Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J Immunol 169:375–383CrossRefGoogle Scholar
  39. Qu H, Yang L, Meng S, Xu L, Bi Y, Jia X, Li J, Sun L, Liu W (2013) The differential antiviral activities of chicken interferon alpha (ChIFN-alpha) and ChIFN-beta are related to distinct interferon-stimulated gene expression. PLoS ONE 8:e59307CrossRefGoogle Scholar
  40. Rabinowich H, Sedlmayr P, Herberman RB, Whiteside TL (1993) Response of human NK cells to IL-6 alterations of the cell surface phenotype, adhesion to fibronectin and laminin, and tumor necrosis factor-alpha/beta secretion. J Immunol 150:4844–4855Google Scholar
  41. Radvanyi LG, Banerjee A, Weir M, Messner H (1999) Low levels of interferon-alpha induce CD86 (B7.2) expression and accelerates dendritic cell maturation from human peripheral blood mononuclear cells. Scand J Immunol 50:499–509CrossRefGoogle Scholar
  42. Rajao DS, Anderson TK, Gauger PC, Vincent AL (2014) Pathogenesis and vaccination of influenza A virus in swine. Curr Top Microbiol Immunol 385:307–326Google Scholar
  43. Santini SM, Lapenta C, Logozzi M, Parlato S, Spada M, Di Pucchio T, Belardelli F (2000) Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med 191:1777–1788CrossRefGoogle Scholar
  44. Scholtissek C, Burger H, Kistner O, Shortridge KF (1985) The nucleoprotein as a possible major factor in determining host specificity of influenza H3N2 viruses. Virology 147:287–294CrossRefGoogle Scholar
  45. Sommereyns C, Paul S, Staeheli P, Michiels T (2008) IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 4:e1000017CrossRefGoogle Scholar
  46. Striz I, Brabcova E, Kolesar L, Sekerkova A (2014) Cytokine networking of innate immunity cells: a potential target of therapy. Clin Sci (Lond) 126:593–612CrossRefGoogle Scholar
  47. Tormo AJ, Letellier MC, Sharma M, Elson G, Crabe S, Gauchat JF (2012) IL-6 activates STAT5 in T cells. Cytokine 60:575–582CrossRefGoogle Scholar
  48. Tovey MG (2002) Oromucosal cytokine therapy: mechanism(s) of action. Taehan Kan Hakhoe Chi 8:125–131Google Scholar
  49. Tovey MG, Lallemand C, Thyphronitis G (2008) Adjuvant activity of type I interferons. Biol Chem 389:541–545CrossRefGoogle Scholar
  50. Veckman V, Osterlund P, Fagerlund R, Melen K, Matikainen S, Julkunen I (2006) TNF-alpha and IFN-alpha enhance influenza-A-virus-induced chemokine gene expression in human A549 lung epithelial cells. Virology 345:96–104CrossRefGoogle Scholar
  51. Yoo JK, Baker DP, Fish EN (2010) Interferon-beta modulates type 1 immunity during influenza virus infection. Antivir Res 88:64–71CrossRefGoogle Scholar
  52. Zaballos A, Gutierrez J, Varona R, Ardavin C, Marquez G (1999) Cutting edge: identification of the orphan chemokine receptor GPR-9-6 as CCR9, the receptor for the chemokine TECK. J Immunol 162:5671–5675Google Scholar
  53. Zhou JH, Wang YN, Chang QY, Ma P, Hu Y, Cao X (2018) Type III interferons in viral infection and antiviral immunity. Cell Physiol Biochem 51:173–185CrossRefGoogle Scholar

Copyright information

© Wuhan Institute of Virology, CAS 2019

Authors and Affiliations

  1. 1.CAS Key Laboratory of Pathogenic Microbiology and ImmunologyInstitute of Microbiology, Chinese Academy of SciencesBeijingChina
  2. 2.University of Chinese Academy of SciencesBeijingChina

Personalised recommendations